EUVIMEDEUVIMED entdecken
Open Access

A Randomized Basket Trial Design for Dose Optimization Based on Bayesian Model Averaging Using Spike‐and‐Slab Priors

Belay Birlie Yimer iD, Kentaro Takeda iD

Statistics in Medicine · 2026-08 · 45 (18-19)

DOI: 10.1002/sim.70700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, online erschienen am 14.08.2026. Verfasst von Belay Birlie Yimer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Europe Ltd., Addlestone, UK. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug, Models, Statistical, Randomized Controlled Trials as Topic, Research Design. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA initiated Project Optimus and issued guidance for dose optimization, recommending randomized parallel dose‐response cohorts to generate additional data at promising dose levels and implying that different dosages may be needed for different indications. In addition to dose optimization, with recent advancements in precision medicine and cancer biology, the development of cancer treatments has shifted toward the search for agents targeted to specific molecular profiles that may appear in more than one type of cancer. The basket trials are clinical trial designs that enable the simultaneous assessment of a new treatment in multiple indications. Concerning the FDA's dose optimization perspective and the recent trend of basket trials in early‐phase clinical trials, this paper proposes a dose‐ranging basket trial design based on a Bayesian model‐averaging approach considering efficacy and toxicity outcomes, where indications and dose levels define baskets. A key benefit of the proposed approach is that it explicitly accounts for the possible heterogeneity of response rates among baskets. Our simulation study shows that the proposed approach outperforms other methods, offering higher statistical power, better control of Type I error rates, precise optimal dose selection, and sample size savings in various scenarios with heterogeneous treatment effects between baskets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dose-Response Relationship, DrugModels, StatisticalRandomized Controlled Trials as TopicResearch DesignAntineoplastic AgentsBayes TheoremHumansComputer SimulationNeoplasms

Stichwörter der Autor:innen

basket trialdose optimizationheterogeneityhierarchical Bayesian modelmodel averaging

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Astellas Pharma Europe Ltd., Addlestone, UK.
  • Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.

ORCID-Profile: Belay Birlie Yimer, Kentaro Takeda

Zitieren

APA

Yimer, B. B., & Takeda, K. (2026). A Randomized Basket Trial Design for Dose Optimization Based on Bayesian Model Averaging Using Spike‐and‐Slab Priors. Statistics in Medicine, 45(18-19). https://doi.org/10.1002/sim.70700

Vancouver

Yimer BB, Takeda K. A Randomized Basket Trial Design for Dose Optimization Based on Bayesian Model Averaging Using Spike‐and‐Slab Priors. Statistics in Medicine. 2026;45(18-19). doi:10.1002/sim.70700

BibTeX
@article{Yimer2026,
  author = {Yimer, Belay Birlie and Takeda, Kentaro},
  title = {A Randomized Basket Trial Design for Dose Optimization Based on Bayesian Model Averaging Using Spike‐and‐Slab Priors},
  journal = {Statistics in Medicine},
  year = {2026},
  volume = {45},
  number = {18-19},
  doi = {10.1002/sim.70700}
}
Kostenlos starten →